anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells

This experimental cellular immunotherapy involves the ex vivo activation and expansion of T cells, which are subsequently "armed" with a bispecific antibody (BiAb) targeting both CD3 on the T cells and CD20 on malignant B cells. Developed at the Barbara Ann Karmanos Cancer Institute, the therapy (often referred to as CD20Bi-armed activated T cells or CD20Bi-ATC) uses the BiAb to bridge the activated T cells to tumor cells, triggering non-MHC-restricted cytotoxicity. The bispecific antibody is typically produced by chemically heteroconjugating anti-CD3 (OKT3) and anti-CD20 (rituximab) monoclonal antibodies. This approach has been investigated in Phase I clinical trials as a consolidation treatment for patients with relapsed or refractory CD20-positive non-Hodgkin lymphoma, often following autologous or allogeneic stem cell transplantation to enhance the graft-versus-lymphoma effect.

Other names

CD20Bi-armed activated T cellsCD-20Bi-armed activated T cellsCD 20Bi-armed activated T cellsOKT3 x Rituxan bispecific antibody-armed T cellsOKT-3 x Rituxan bispecific antibody-armed T cellsOKT 3 x Rituxan bispecific antibody-armed T cellsanti-CD3 x anti-CD20 armed T cellsanti-CD-3 x anti-CD20 armed T cellsanti-CD 3 x anti-CD20 armed T cells